Form 4: Kairos Pharma Director Gains 19,084 RSUs

Kairos Pharma Director Rahul Singhvi acquired 19,084 restricted stock units, vesting fully on the first anniversary of the grant date.

Summary

• Rahul Singhvi, a Director at Kairos Pharma, LTD. (KAPA), acquired 19,084 Restricted Stock Units (RSUs) on October 8, 2025.
• The RSUs were issued under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
• These 19,084 RSUs are scheduled to vest in full on October 8, 2026, which is the first anniversary of the grant date.
• Following this transaction, Mr. Singhvi beneficially owns a total of 49,204 RSUs that remain subject to vesting.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of RSUs to a director is a routine compensation event, aligning interests but not indicating significant operational news. The vesting schedule provides a future incentive.

Positives

• Director Rahul Singhvi received a grant of 19,084 Restricted Stock Units (RSUs), aligning his interests with long-term shareholder value.
• The grant is part of the company's 2023 Equity Incentive Plan, indicating an ongoing strategy to use equity compensation to attract and retain talent.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• The value of the RSUs is tied to the future stock price of Kairos Pharma, LTD., exposing the recipient to market fluctuations.
• The RSUs are subject to vesting conditions, meaning the recipient must remain with the company for a specified period to fully realize the benefit.

Future Outlook

The filing indicates a commitment to long-term equity incentives for directors, suggesting a strategy to align management interests with shareholder value over time. The vesting schedule for the RSUs extends into the future, implying continued engagement of the director.

Industry Context

Equity compensation, particularly through Restricted Stock Units, is a standard practice in the biotechnology and pharmaceutical industries to incentivize executives and directors, aligning their long-term interests with company performance and shareholder returns.

Comparison to Industry Standards

• The use of RSUs for director compensation is a common practice across various industries, including biotech and pharma, aligning with governance best practices to incentivize long-term performance.
• Companies like Amgen, Gilead Sciences, and Moderna frequently utilize RSU grants as a significant component of their executive and director compensation packages, often with multi-year vesting schedules similar to the one described.
• The grant of 19,084 RSUs, while specific to Kairos Pharma's compensation structure, is within the typical range for non-employee director equity grants in small to mid-cap biotech firms, which often range from 10,000 to 50,000 units annually depending on company size and stock price.

Corporate Governance

Related Party Transactions

• The RSU grant to a director is a standard related party transaction for compensation purposes, disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, potentially encouraging decisions that benefit the stock price. It also represents a minor potential for future dilution upon vesting.
• Employees: The use of an equity incentive plan suggests a broader framework for employee and director compensation, which can positively impact morale and retention.

Next Steps

• The 19,084 RSUs are scheduled to vest in full on October 8, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Kairos Pharma, nor does it provide insights into operational performance, financial health, or strategic shifts that would warrant a change in investment recommendation. It primarily serves to disclose insider ownership changes and alignment of interests.

Keywords

Kairos Pharma, KAPA, Rahul Singhvi, Form 4, Restricted Stock Units, RSUs, Insider Transaction, Equity Incentive Plan, Director Compensation